

Molecular Haemato-Oncology Trial Schedule 2026 – 2027

Accredited Programmes	Trial issue	APR 26	MAY 26	JUN 26	JUL 26	AUG 26	SEP 26	OCT 26	NOV 26	DEC 26	JAN 27	FEB 27	MAR 27
BCR::ABL1 and AML Translocation Identification	3	X				X				X			
BCR::ABL1 Kinase Domain Variant (Mutation) Status	3			X				X				X	
BCR::ABL1 Major Quantification	3		X				X				X		
BCR::ABL1 Minor Quantification	3		X				X				X		
BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia	3	X			X					X			
FLT3 Mutation Status	3				X				X				X
IG/TCR Clonality Status	3	X				X				X			
KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease	3		X				X				X		
Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia	3			X				X					X
Myeloproliferative Neoplasms Diagnostic Testing ¹	4		X			X			X			X	
NPM1 Mutation Status	3				X				X				X
Paediatric Acute Leukaemia Translocations	3			X				X				X	
Post-Stem Cell Transplant Chimerism Monitoring	5		X		X			X		X		X	

Non-accredited Programmes	Trial Issue	APR 26	MAY 26	JUN 26	JUL 26	AUG 26	SEP 26	OCT 26	NOV 26	DEC 26	JAN 27	FEB 27	MAR 27
Lymphoid Gene Panels	2						X ²						X ³
Measurable Residual Disease for Acute Myeloid Leukaemia by Molecular Methods	2					X							X
Measurable Residual Disease for Lymphoid Neoplasms by Molecular Methods	2			X					X				
Myeloid Gene Panels	2					X ²						X ³	

1. Please note, only the JAK2 p.V617F aspect of testing is currently accredited. We are working towards accreditation for the other markers. 2. Includes educational variant interpretation; 3. Technical focus.
Molecular Trial Schedule 2026-2027 - Version: 1.0. Index: Molecular 796. Printed: 06-Oct-2025 12:38
Please note that this is a guide only. UK NEQAS for Leucocyte Immunophenotyping reserves the right to cancel or vary the number of shipments. Please note that your participation entitles you to the service and not the number of shipments.